May 8 |
2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript
|
May 8 |
2seventy bio GAAP EPS of -$1.01 misses by $0.20, revenue of $12.4M misses by $1.69M
|
May 8 |
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
|
May 7 |
2seventy bio Q1 2024 Earnings Preview
|
May 3 |
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
|
Apr 25 |
Bristol-Myers posts Q1 beat despite growth headwinds
|
Apr 5 |
Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
|
Apr 5 |
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
|
Apr 3 |
2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
|
Apr 1 |
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
|